Emsam (Selegiline) Patent Expiration, LOE Window & CMS Spending
Emsam (Selegiline) by Somerset: Off-Patent Genericized (AB Competition), 5 AB generics, $17.2M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Somerset |
| FDA Application & Pathway | N021336 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 5 |
| 2024 CMS Total Public Spend | $17.2M |
| 2024 Medicare Part D Spend | $12.5M |
| 2024 Medicaid Spend | $4.6M |
| Reported Wholesale Price Change (CA SB 17) | 9 WAC filings (max 18.0% 2-yr change) |